Literature DB >> 15864738

T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression.

Elena Klyushnenkova1, Joseph D Mosca, Valentina Zernetkina, Manas K Majumdar, Kirstin J Beggs, Donald W Simonetti, Robert J Deans, Kevin R McIntosh.   

Abstract

Human mesenchymal stem cells (MSCs) were evaluated for their ability to activate allogeneic T cells in cell mixing experiments. Phenotypic characterization of MSCs by flow cytometry showed expression of MHC Class I alloantigens, but minimal expression of Class II alloantigens and costimulatory molecules, including CD80 (B7-1), CD86 (B7-2), and CD40. T cells purified from peripheral blood mononuclear cells (PBMCs) did not proliferate to allogeneic MSCs. Lack of response was not due to a deficiency of costimulation, since retroviral transduction of MSCs with either B7-1 or B7-2 costimulatory molecules did not result in lymphoproliferation. Although these results suggested that MSCs were immunologically inert or potentially tolerogenic, T cells cultured with MSCs produced IFN-gamma and displayed secondary kinetics to restimulation with PBMCs, indicating alloantigen priming rather than tolerance induction by the MSCs. To determine whether MSCs suppressed alloreactive T cells, MSCs were added to primary mixed lymphocyte reaction (MLR) cultures. MSCs suppressed cell proliferation when added at the initiation of culture or when added to an ongoing MLR culture. Suppression was dose-dependent, genetically unrestricted, and occurred whether or not MSCs were pretreated with IFN-gamma. MSCs in transwell chambers suppressed primary MLR cultures, indicating that suppression was mediated by soluble molecules. Analysis of cytokines in suppressed MLR cultures demonstrated up-regulation of IFN-gamma and IL-10, and down-regulation of TNF-alpha production relative to control cultures. We conclude that MSCs can initiate activation of alloreactive T cells, but do not elicit T cell proliferative responses due to active suppressive mechanisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864738     DOI: 10.1007/s11373-004-8183-7

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  166 in total

1.  Multipotent Mesenchymal Stromal Cells for Autoimmune Diseases.

Authors:  Alan Tyndall
Journal:  Transfus Med Hemother       Date:  2008-07-17       Impact factor: 3.747

Review 2.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

3.  Allogeneic mesenchymal stem cells transplantation in patients with refractory RA.

Authors:  Jun Liang; Xia Li; Huayong Zhang; Dandan Wang; Xuebing Feng; Hong Wang; Bingzhu Hua; Bujun Liu; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2011-08-12       Impact factor: 2.980

Review 4.  Emerging therapeutic approaches for multipotent mesenchymal stromal cells.

Authors:  Paolo F Caimi; Jane Reese; Zhenghong Lee; Hillard M Lazarus
Journal:  Curr Opin Hematol       Date:  2010-11       Impact factor: 3.284

Review 5.  The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.

Authors:  Jeffery J Auletta; Amelia M Bartholomew; Richard T Maziarz; Robert J Deans; Robert H Miller; Hillard M Lazarus; Jeffrey A Cohen
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

Review 6.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Jay K Kolls; Luis A Ortiz; Angela Panoskaltsis-Mortari; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2008-07-15

Review 7.  Cellular therapy of systemic sclerosis.

Authors:  Jacob M van Laar; Alan Tyndall
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

Review 8.  Inflammatory bowel disease: Moving toward a stem cell-based therapy.

Authors:  Giacomo Lanzoni; Giulia Roda; Andrea Belluzzi; Enrico Roda; Gian Paolo Bagnara
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

9.  Study of the quantitative, functional, cytogenetic, and immunoregulatory properties of bone marrow mesenchymal stem cells in patients with B-cell chronic lymphocytic leukemia.

Authors:  Charalampos Pontikoglou; Maria-Christina Kastrinaki; Mirjam Klaus; Christina Kalpadakis; Pavlos Katonis; Kalliopi Alpantaki; Gerassimos A Pangalis; Helen A Papadaki
Journal:  Stem Cells Dev       Date:  2013-02-01       Impact factor: 3.272

Review 10.  Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Authors:  Robert D Wyse; Gary L Dunbar; Julien Rossignol
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.